Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 7 clinical trials
Open-label Access to Dolutegravir for HIV-1 Infected Children and Adolescents Completing IMPAACT Studies P1093 and P2019

Dolutegravir is a potent integrase strand transfer inhibitor. Abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) is a fixed dose combination regimen containing two nucleoside reverse transcriptase

dolutegravir
abacavir
HIV Vaccine
hiv-1 rna measurement
antiviral drugs
  • 188 views
  • 24 Oct, 2022
  • 16 locations
Cartography of Virologic Reservoir Related to Antiretroviral Concentrations in HIV-1 Chronic Patients Treated by a First Line Treatment Containing Dolutegravir and Associated Nucleoside / Nucleotide Reverse Transcriptase Inhibitors Backbone (DOLUVOIR)

The main objective of the study is to characterize the diffusion of dolutegravir and associated backbone (abacavir/lamivudine or tenofovir/emtricitabine) in HIV-1 chronic patients in the main

  • 0 views
  • 22 Mar, 2022
  • 1 location
Randomised Double-Blind Placebo-Controlled Phase 3 Trial of Triumeq in Amyotrophic Lateral Sclerosis (LIGHTHOUSE II)

To determine if Triumeq improves survival in Amyotrophic Lateral Sclerosis (ALS) compared with placebo

pregnancy testing
riluzole
primary lateral sclerosis
  • 0 views
  • 19 Oct, 2022
  • 7 locations
Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant Women. (APR)

The purpose of the Antiretroviral Pregnancy Registry (Registry) is to detect any major teratogenic effect involving any of the Registry drugs when administered to pregnant women. Registration is voluntary and confidential with information obtained from the health care provider. A Registry-assigned identifier allows for follow-up capability. Information on subjects is …

antiretroviral
antiretrovirals
prenatal
HIV Vaccine
antiretroviral agents
  • 70 views
  • 04 May, 2022
  • 1 location
Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women. (PANNA)

Due to the potential for pregnancy-induced changes in the pharmacokinetics of medication, one cannot assume that the currently licensed doses of the medication to be tested under this protocol lead to adequate exposure in an HIV-infected pregnant woman. For the agents under study no or limited pharmacokinetic data during pregnancy …

hiv antibody
antibody test
antiretroviral
HIV Vaccine
hiv antibodies
  • 156 views
  • 07 Oct, 2022
  • 16 locations
Outcomes of HIV Infected Individuals After Ten Years on Antiretroviral Treatment

Study Title: Outcomes of HIV infected individuals after ten years on antiretroviral treatment Short Title/Study ID: ALT cohort Protocol Version and Date: Version 1.0 June 2013 Clinical Phase: NA Methodology: Prospective observational study Study Duration: 01 January 2014- 30th June 2025 Study Centre(s): Single centre (Infectious Diseases Institute, Kampala, Uganda) …

antiretroviral agents
  • 7 views
  • 21 Jan, 2021
  • 1 location
Antiretroviral Pregnancy Registry (APR)-Risk of Birth Defects

The APR began as the 'Zidovudine in pregnancy Registry' in January 1989 and became the 'Antiretroviral Pregnancy Registry' in January, 1993. The purpose of the APR is to detect any major teratogenic effects involving any of the Registry drugs when administered to pregnant HIV positive women. The Registry is intended …

antiretroviral
abacavir
HIV Vaccine
zidovudine
lamivudine
  • 26 views
  • 30 Jan, 2022
  • 1 location